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Abstract 
Immunocompromised patients are prone to develop various pulmonary complications. The range of
diagnostic possibilities is wide, infection being the commonest cause. Non-invasive diagnostic tests are
often unrewarding. In this study, we have evaluated the diagnostic efficacy and safety of fibreoptic
bronchoscopy in immunocompromised patients with pulmonary infiltrates. Patients tolerated the proce-
dure well. This technique identified the etiology in upto 75% of cases. After treatment based on the
result of bronchoscopy, 63% patients improved and were discharged (JPMA 48: 311,1998).
Introduction 
Immunocompromised patients are prone to develop various pulmonary complications and appearance
of lung infiltrates in such patients is not an uncommon occurrence. Infection remains the commonest
cause of pulmonary infiltratesbut upto 30% of cases may be due to non-infectious causes such as
radiation and drug induced pneumonitis, metastases, hemorrhage and pulmonary embolism. Chest
radiographic patterns are often non-specific and sputum and blood analyses may be unrevealing.
Failure to identify the causative organism could delay the initiation of specific therapy or result in
empirical use of large numbers of expensive and potentially toxic antibiotics. Concomitantly, these
patients may have bleeding diathesis that can make invasive procedures hazardous. In this study, we
have evalUated the diagnostic efficiency and safety of fibreoptic bronchoscopy in
immunocompromised individuals with radiologically evident pulmonary infiltrates.
Patients and Methods 
We performed an analysis of immunocompromised patients, admitted between June, 1992 and June,
1994 at the Aga Khan University Hospital, who underwent fibreoplic bronchoscopy for establishing the
etiology of pulmonary infiltration. Information was collected about clinical history, physical
examination, radiology and laboratory investigations including sputum and blood cultures. The main
indication for fibreoptic bronchoscopy in these invididuals was failure to respond to empirical
antibiotic therapy and/orfailureto isolate the causative organism by non- invasive tests. The procedure
was not performed in those individuals who had severe hypoxia (PaO2 <60 mm Hg despite maximal
oxygen therapy) or severe thrombocytopenia (platelet count x10 /1). Patients with a prolonged
prothrombin time (>15 seconds) received fresh frozen plasma immediately before the procedure.
Bronchoscopy was perfonned under local anesthesia and intravenous sedation. Bronchial tree was
inspected for endobronchial lesion and washing was sent for bacterial, fungal and mycobacterial stains
and cultures and for cytology.
Stain for Pneumocystis was perfonned in selected cases. Results of fibreoptic bronchoscopy and final
outcome of hospital stay was noted.
Results 
Total of 19 fibreoptic bronchoscopies were performed on 18 patients, one had the procedure perfonned
twice over a 3 month period. Mean age was 45.2 (range 18-70) years, with a male to female ratio of
3.5:1. All the cases were immunocompromised, of these 17 had underlying malignancy and had
received chemotherapy and/or ‘high dose corticosteroid, one had AIDS and one had Sjorgen’s
syndrome being treated with high dose corticosteroid. Clincal features included fever (90%), chest pain
(45%), dyspnoea(33%) and haemoptysis (5%). All had pulmonary infiltrates on chest radiograph, the
infiltrates were unilateral in 53% and bilateral in 47% cases. Evidence of cavitation was seen in 31%
and pleural effusion in 31% patients. Pneumothorax was seen in one (5%) patient.
Initial laboratory investigation revealed that nearly half of the patients had hemoglobin under 10 mg/dl,
one third had platelet count below 100x109/l and a quarter had pmthrombin time more than 16 seconds.
White cell count was below 2x109/l in 26% and electrolyte imbalance was seen in 21% subjects.
Patients tolerated the procedure well, the only complication being brisk hemorrhage in one case, which
settled with conservative therapy. There was no mortality associated with the procedure.
The Table summarizes the fmdingsofbronchoscopy and correlates them withchanges on chest
radiograph. It illustrates that this technique had a potential to identify the etiology in upto 75% of cases.
Most cavitating pneumonia were caused by Aspergillus and Staphylococcus aureus, whereas
tuberculosis produced noncavitating pneumonia in immunocomproniised patients. After treatment
based on the results of bmnchoscopy, 12 (63%) patients improved and were discharged, whereas 37%
died during their hospital stay.
Discussion 
Management of inununocompromised patients with pulmonaiy infiltrates isa difficult clinical problem.
The range of diagnostic possibilities is wide, infection being the commonest cause. Non-invasive
diagnostic tests are often unrewarding. Although guidelines for management have been developed1,2 ,
they are mostly based upon single institution studies from Western countries and are not necessarily
relevant to physicians mother geographic locations. However, before performing an invasive
procedure, thought must be given to what changes in management may be made once results are
known.
At the time of presentation, the physician has to make a decision whether to start empirical therapy or
to perfonu an invasive diagnostic test Fibreoptic bronchoscopy is well tolerated, is safe and is often the
initial procedure of choice3. It provides access to the lower respiratory tract secretions and tissue ma
number of ways:
a) bronchial washing, collection of pooled secretions from airways,
b) bronchoalveolar lavage, large volume of saline (100-240 mls) is instilled and then collected by
suction from a distal airway;
c) bronchial brushing, a brush is projected through a catheter into the desired segment and samples are
obtained; and
d) biopsy, either of the airway (bronchial) or the alveoli (transbronchial).
Other invasive investigations are transtracheal aspiration, percutaneous needle aspiration, core needle
biopsy of the lung and open lung biopsy. The choice of procedure depends on the expected yield and
the complication rate of the procedure, suspected diagnosis and the clinical situation.
In a study of 118 patients4, the yield of fibreoptic bronchoscopy with brushing, lavage and
transbronchial biopsy was found to be 73%. The pattern of infection varied
according to the cause of immunosuppression. Pneumocystis carinii was the predominant pathogen in
HIV positive patients, cytomegalovirus in transplant recipients and bacteria (including mycobacteria) in
patients receiving immunosuppressive and/or cytotoxic drug therapy. Our study confinns the usefulness
of fibreoptic bronchoscopy in identifying the organisms that leads to rationalizing of antibiotic therapy.
In our series population aspergillus, pseudomonas, staphylococcus and mycobacterium tuberculosis
were the most commonly identified organisms. TB often presents in an atypical manner in
immunocompromised patients i.e., non- cavitating or lower lobe lesion and this fact has been observed
in other studies5.
Growth of bacteria and Candida from bronchial washing should always be viewed cautiously because
of the possibility of colonization and contamination from upper airways. To cjrcumvent this problem,
protected brush specimen have been used but it may not always provide an uncontaminated specimen6.
Secondly, quantitation of the organism recovered may help to determine whether the organism is an
upper respiratory contaminant or represents lower respiratory infection7. In general, if the specimen has
>105 colony forming units/mi then it represents pneumonia. With the use of more myelosuppressive
combination chemotherapy, the risk of developing pulmonary and other infections has increased. The
choice in early management is mainly limited to empincal therapy or use of an invasive procedure to
identify the causative agent. Our study has shown that the use of fibreoptic bronchoscopy in
experienced hands is safe and is able to identify the organism in 74% of cases. Some of the organisms
appeared to be the definite cause (fungal and mycobactenal) whereas others (bacterial) were probable
cause of the pulmonary infiltrate. However, even this knowledge was helpful as it helped to rationalize
the drug therapy. Other causes of an abnormal radiograph such as endobronchial obstruction (leading to
distal collapse or pneumonia) can also be identified. In 21% cases the results were non-diagnostic. We
now need prospective randomized studies to assess whether early use of invasive procedures would
influence the final outcome of these patients.
References 
1. Rosenow EC. Wilson WR, Cockerill FR. Pulmonary disease in the immunocompromised host. Mayo
Clin. Proc., 1985;60(7):473-87.
2. Staszewski H. Diffuse pulmonary infiltrates in immunocompromised patients. Reconciling theory
and practice. Post Grad. Med., 1993;94( 1 ):69.78.
3. Matthay RA. Farmer WC, Odero D. Diagnostic fibreoptic bronchoscopy in the immunocompromised
host with pulmonary infiltrates. Thorax., 1977;32:539-45.
4. Heurlin N, Brattstrom C, Lonnqvist Bet al. Aetiology of pulmonary diseases in
immunocompromised patients. Eur. Resp.J. 1991 ;4( 1): 10-18.
5. Asimos AW, Ehrhardt J. Raidographic presentation of pulmonary tuberculosis in severely
immunocompromised HIV-seropositive patients. Am. J. Emerg. Med. 1996; 14(4):359-63.
6. Wimberley N, Faling LJ, Bartlett JG et al. A fiberoptic bronchoscopy technique to obtain
uncontaminated lowerairway secretions forbacterial culture. Am. Rev. Respir. Dis., 1979;119:337-43.
7. Winterbauer RH, Hutchinson JF, Reinhardt GNM et al. The use of quantitative cultures and antibody
coating of bacteria to diagnose bacterial pneumonia by fibreoptic bronchoscopy. Am. Rev.Respir.
Dis.,1983;128:98-103.
